Rabies Immunoglobulin is a human rabies immune globulin (HRIG) approved for the temporary, passive prevention of rabies infection in individuals of any age. It is recommended for immediate use following contact with a rabid or potentially rabid animal. Rabies Immunoglobulin should be administered in conjunction with a complete regimen of rabies vaccine.

Rabies

Post-exposure prophylaxis:

• For wound infiltration and intramuscular use.
• A single dose of Rabies Immunoglobulin with a full course of rabies vaccine
• 20 IU/kg body weight Rabies Immunoglobulin  
• Do not exceed the recommended dose.  
• Do not repeat Rabies Immunoglobulin doses once vaccine treatment is initiated.
• Administer as soon as possible after exposure
• Infiltrate area around wound with full dose
• Inject any remaining Rabies Immunoglobulin intramuscularly, at a site distant from the site of rabies vaccine administration 

The most common adverse reactions observed in adult subjects were-

• injection site pain
• headache
• muscle pain
• joint pain
• dizziness
• fatigue

Pain at injection site

Headache

Muscle Pain

Fatigue

• Do not administer Rabies Immunoglobulin to individuals who have completed rabies pre- or postexposure prophylaxis as it may disrupt the anamnestic response to the rabies vaccine.
• Hypersensitivity reactions, including anaphylaxis, can occur with Rabies Immunoglobulin, particularly in IgA deficient patients with antibodies against IgA, who are at an increased risk. Ensure immediate access to epinephrine for the treatment of any acute severe hypersensitivity reactions.
• Caution should be exercised regarding interference with live attenuated virus vaccines.
• Given that Rabies Immunoglobulin is derived from human plasma, there is a potential risk of transmitting infectious agents such as viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.